

Venue: Hall 1

Presentation: Thursday 26 July, 12:30-14:30

The Poster Exhibition is open from Tuesday 24 - Thursday 26 July from 10:00 to 18:30.

Late breaker posters are displayed for the duration of the conference (Tuesday-Thursday) in the Poster Exhibition area.

Track A: Basic and translational research

PEA001	Host cellular factors and latency
LBPEA001	<p>Surface signature of HIV latently-infected cells revealed using direct hybridization-based digital counting</p> <p><i>H.S. Sperber, L.R. Chavez, S.K. Pillai</i> United States</p>
PEA002-A005 Cellular and tissue reservoirs of HIV/SIV	
LBPEA002	<p>Characterization of the HIV-1 reservoir in CD32+ CD4+ T cells</p> <p><i>G. Darcis, N. Kootstra, B. Hooibrink, T. van Montfort, S. Jurriaans, M. Bakker, C. van Lint, B. Berkhout, A. Pasternak</i> Netherlands</p>
LBPEA003	<p>ART does not inhibit antigen presenting cell-mediated HIV trans infection</p> <p><i>G. Rappocciolo, D. Delucia, N. Sluis-Cremer, C. Rinaldo</i> United States</p>
LBPEA004	<p>Evidence of HIV replication in tissue samples at autopsy from donors on cART with undetectable HIV RNA in blood</p> <p><i>V. Natarajan, Y. Badralmaa, H.C. Lane</i> United States</p>
LBPEA005	<p>Single-cell RNA-seq reveals a distinct transcriptomic signature of CD32+ CD4+ T cells from HIV+ individuals on suppressive therapy</p> <p><i>M. Abdel-Mohsen, A. Kossenkov, C. Tomescu, S. Vadrevu, L. Giron, K. Lynn, K. Mounzer, P. Tebas, L. Montaner</i> United States</p>
PEA006	Quantifying HIV/SIV reservoirs and rebounding virus
LBPEA006	<p>FDA-approved chemotherapeutic drugs that inhibit VEGF, RAF-1, B-RAF and the proteasome reverse HIV latency without global T cell activation</p> <p><i>I. Munoz-Arias, E. Gibson, E. Hanhauser, G. Wu, C. Thanh, M.A. Mohsen, L. Hogan, K. Hobbs, B. Howell, S. Pillai, S. Deeks, T. Henrich</i> United States</p>
PEA007-A008 Eliminating/Silencing latency	
LBPEA007	<p>Broadly neutralizing antibodies reduce latent HIV infection in a primary TCM model of latency</p> <p><i>R.S. Resop, G. Mantus, A.B. Macedo, R. Lynch, A. Bosque</i> United States</p>
LBPEA008	<p>Dendritic cells drive antigen-specific exposure and immune elimination of HIV latently infected CD4+ T cells</p> <p><i>J. Kristoff, N. Sluis-Cremer, M. Palma, T. Garcia-Bates, P. Gupta, C. Rinaldo, R. Mailliard</i> United States</p>
PEA009	Immunotherapy

LBPEA009

ABX464, by binding the CBC 80/20 complex, enhances pre-mRNA splicing, resulting in the generation of novel HIV-derived RNA species and in increased expression of the anti-inflammatory miR124

J. Tazi, A. Vautrin, L. Manchon, A. Garcel, N. Campos, K. Chebli, D. Scherrer, J.-M. Steens, H. Ehrlich
France

PEA010

HIV controllers (including post-treatment controllers) and long term non-progressors

LBPEA010

Low CCR5 expression protects specific CD4+ T cells of HIV controllers from viral entry

M. Claireaux, R. Robinot, I. Staropoli, A. Brelot, M. Héry, M. Patgaonkar, A. Nouël, S. Volant, E. Perthame, F. Boufassa, D. Zucman, P. de Truchis, O. Lambotte, L.A. Chakrabarti
France

PEA011

Correlates of immune protection

LBPEA011

Autophagy suppresses mucosal HIV-1 replication and improves clinical outcomes for HIV-1 infected individuals

A. Cloherty, N. van Teijlingen, J. van Hamme, R. Sarrami-Forooshani, N. Kootstra, T. Geijtenbeek, C. Ribeiro
Netherlands

PEA012

Immunotherapy (including broadly neutralizing antibodies)

LBPEA012

Susceptibility to anti-HIV broadly neutralizing antibodies is concordant in plasma vRNA and PBMC proviral DNA compartments and supports potential utility of screening prior to therapy

J. Reeves, Y. Zheng, Y. Lie, L. Burke, B. Taiwo, C. Petropoulos, P. Tebas, M. Caskey, K. Bar
AIDS Clinical Trials Group
United States

Track B: Clinical research

PEB013

HIV-2

LBPEB013

Long-term immunologic responses to treatment among HIV-1, HIV-2 and HIV-1/2 dually infected patients in Côte d'Ivoire

C. Adje epse Toure, P. Minchella, M. Aka Kouakou Adade, G. Zhang, K. Diallo, J. Hedje
Cote d'Ivoire

PEB014-B015 Tuberculosis

LBPEB014

Systematic empirical versus test-guided anti-tuberculosis treatment impact in severely immunosuppressed HIV-infected adults initiating antiretroviral therapy with CD4 cell counts < 100/mm³: Final results from the STATIS (ANRS 12290) randomized trial

E.X. Blanc, A.D. Badje, M. Bonnet, D. Gabillard, E. Messou, C. Muzoora, S. Samreth, D.B. Nguyen, L. Borand, A. Domergue, N. Natukunda, S. Juchet, S. Eholie, S. Domoua, X. Anglaret, D. Laureillard
France

LBPEB015 Adherence to Bedaquiline and antiretroviral therapy predicts mortality in the treatment of multi- and extensively drug-resistant tuberculosis (M/XDR-TB) HIV co-infected patients in KwaZulu-Natal, South Africa
C. Hwang, G. Friedland, R. Amico, A. Daftary, J. Zelnick, B. Seepamore, A. Wolf, R. Boodram, B. Maharaj, C. Orrell, N. Padayatchi, M. O'Donnell, PRAXIS Study Group
 United States

PEB016 Malignancies (AIDS and non-AIDS)
LBPEB016 Trends in cancer risk in HIV-infected people in South Africa (2004 - 2014)
T. Dhokotera, J. Bohlius, A. Spoerri, M. Egger, J. Ncayiyana, V. Olago, E. Singh, M. Sengayi
 South Africa

PEB017-B018 ART in highly treatment-experienced persons
LBPEB017 Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial
J.-M. Molina, K. Squires, P. Sax, P. Cahn, J. Lombaard, E. DeJesus, M.-T. Lai, X. Xu, A. Rodgers, L. Lupinacci, S. Kumar, P. Sklar, B.-Y. Nguyen, G. Hanna, C. Hwang, E. Martin
 United States

LBPEB018 The effect of delayed switch to second-line ART and confirmed failure monitoring on mortality among South African adults
H. Bell Gorrod, A. Boulle, M. Fox, R. Wood, H. Prozesky, F. Tanser, M.-A. Davies, M. Schomaker
 United Kingdom

PEB019 Regimen simplification and switch studies
LBPEB019 Preliminary virologic outcomes and prevalence of integrase strand transfer inhibitor resistance mutations among highly treatment experienced patients receiving dolutegravir in Botswana
K.K. Seatla, A. Avalos, T. Mphoyakgosi, S. Moyo, M. Mogwele, M. Mine, W. Choga, C. Petlo, D. Ramaabya, T. Gaolathe, I. Kasvosve, J.N. Jarvis, S. Gaseitsiwe
 Botswana

PEB020 Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring
LBPEB020 Preliminary virologic outcomes of patients switched to dolutegravir containing regimens for toxicities, treatment failures and regimen optimization at a large urban hospital in Botswana
A. Avalos, T. Gaolathe, R. Mokgwathise, D. Ramaabya, K. Lesego, M. Zwinila, M. Kapanda, C. Petlo, K. Seatla, S. Gaseitsiwe, The Botswana Epidemiological ART Treatment Cohort Study
 Botswana

PEB021 Cure interventions
LBPEB021 Administration of CC-11050, a phosphodiesterase 4 inhibitor, is well tolerated but does not significantly decrease immune activation in treated HIV+ persons
A. Boulougoura, E. Gabriel, E. Laidlaw, A. Pau, A. Poole, J. Higgins, A. Rupert, A. Kibiy, V. Khetani, K. Arakawa, P. Kumar, L. Sereti
 United States

PEB022 Complementary and traditional medicines

LBPEB022 Loss of detectable HIV CD4+ T cell RNA following single-dose brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma
C.-C. Wang, C. Thanh, E. Gibson, M. Ball-Burack, L. Hogan, B. Descours, N. Jones, A. Carvidi, J. Milush, S. Deeks, T. Henrich
 United States

PEB023 ARV management strategies in paediatric and adolescent populations
LBPEB023 Pharmacokinetic and 4-week safety/efficacy of dolutegravir (S/GSK1349572) dispersible tablets in HIV-infected children aged 4 weeks to < 6 years: Results from IMPAACT P1093
T. Ruel, E. Acosta, R. Singh, C. Alvero, T. Fenton, K. George, S. Popson, E. Townley, R. Hazra, C. Brothers, C. Vavro, A. Buchanan, A. Wiznia, IMPAACT P1093 Team
 United States

Track C: Epidemiology and prevention research

PEC024-C025 Epidemiology of HIV in MSM
LBPEC024 Prevalence and correlates of HIV infection among men who have sex with men in Hanoi, Vietnam
H. Bui, G. Le, D. Vu, L. An, P. Truong, R. Shiraishi, I. Zablotska-Manos, J. Blandford, A. Abdul-Quader, H. Van, L. Maher
 Australia

LBPEC025 High prevalence of sexually transmitted infections (STIs) among men who have sex with men (MSM) in Vietnam and the need of STIs interventions
D. Vu, G. Le, H. Bui, L. An, H. Van, P. Truong, L. Maher, R. Shirayshi, H. Bui, A. Abdul-Quader, J. Blandford
 Vietnam

PEC026-C027 Surveillance in key population groups
LBPEC026 Occupational hazards of traditional healers in rural South Africa: Bloodborne pathogen exposures and risk of HIV transmission
C. Audet, S. Ngobeni, M. Mkansi, F. Wafawanaka, M. Aliyu, K. Kahn, R. Wagner
 United States

LBPEC027 Progress towards achieving HIV epidemic control among people who inject drugs in Myanmar: Findings from the 2017-18 bio-behavioral survey among PWID
S. Hone, M.Y. Aung, S. Phyu, R. Sutton, K.M. Tun, M. Jacobs, Y. Wu, M. Lahuerta
 United States

PEC028-C029 Measuring the epidemic through population-based surveys, including the undiagnosed fraction
LBPEC028 Progress towards UNAIDS 90-90-90 goals among people living with HIV in Tanzania: Results from Tanzania HIV Impact Survey (THIS) 2016-17
R. Magina Mdodo, M. Kitembe, K. Lavilla, R. McCree, S. Jonnalagadda, E. Gummerson, V. Mugisha, G. Somi, A. Mulokozi, E. Karugendo, P. Stupp, E. Matiko, G. Mgomella, M. Balinda, A. Mbaraka, S. Findley, M. Mayasa, A. Salim Ali, F. Khalid, F. Masha, B. Parekh, J. Justman, A. Voetsch, D. Lowrance
 Tanzania, United Republic of

LBPEC029 **Factors associated with viral load suppression among PLHIV in Tanzania; Results from Tanzania HIV Impact Survey (THIS) 2016-17: Implications to the ART programs**
C. Makafu, J. James, E. Karugendo, R. Mdodo, E. Gummerson, G. Mgomela, A. Ramadhani, J. Mushi, S. Jonnalagadda, K. Lavilla, J. Zelothe, G. Somi, E. Luaula, C. Vesper, B. Simpoli, V. Mugisha, K. Jackson, R. McCree, O. Malewo, W. Nega, J. Justman
 Tanzania, United Republic of

PEC030 **Identifying optimal service models**
 LBPEC030 **Does faster service equal better retention: Assessing fast track services in Lusaka, Zambia**
J. Pryn, M. Roy, I. Sikazwe, M. Mukumbwa-Mwenechanya, P. Somwe, E. Kalunkumya, M. Lumpa, A. Sharma, N. Padian, E. Geng, C. Holmes, C. Bolton
 Zambia

PEC031 **Other new prevention tools**
 LBPEC031 **Digital pre-exposure prophylaxis (PrEP): Near real-time remote capture of medication ingestion for clinical use in trials and adherence support**
S.H. Browne, N.J. Hanan, T.F. Katsivas, A.J. Tucker, A. Umlauf, F. Vaida, J.F. Rooney, C.A. Benson, T.F. Blaschke
 United States

PEC032 **Reaching and recruiting key populations for HIV services (online, offline, online-to-offline)**
 LBPEC032 **Use of geolocation-based push messaging from a social media platform to promote HIV testing among MSM - Beijing, China, 2015-2016**
D. Podson, Y. Ma, F. Yu, Z. Chen, G. Mi, L. Wang
 China

PEC033 **Innovative HIV testing strategies (peer-led testing, peer-mediated testing, self-testing with and without online/offline support, use of fourth generation and recency assays)**
 LBPEC033 **Impact of a digital HIV self-testing strategy on referrals, new infections and linkage to care: Results from a transition to scale cohort study in South Africa**
N. Pai, A. Esmail, G. Marathe, S. Oelofse, M. Pretorius, M. Fadul, M. Smallwood, J. Daher, R. Janssen, P. Saha-Chaudhuri, N. Engel, K. Dheda
 Canada

PEC034-C035 **Demonstration and pilot projects for PrEP, PEP, male circumcision**
 LBPEC034 **Different PrEP modalities for different people: switches between daily and event-driven PrEP among MSM and TGP**
E. Hoornenborg, L.N. Coyer, R.C.A. Achterbergh, M.F. Schim van der Loeff, U. Davidovich, H.J.C. de Vries, M. Prins, on behalf of the Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative (H-TEAM)
 Netherlands

LBPEC035 **Syphilis acquisition and dosing schedule for pre-exposure prophylaxis (PrEP) users in Taiwan PrEP demonstration project**
H.-J. Wu, C. Strong, S.W.-W. Ku, C.-W. Li, C.-Y. Cheng, H.-C. Tsai, C.-Y. Lee, S.-T. Huang, N.-Y. Ko, Y.-F. Huang, TW-CDC
 Taiwan, China

PEC036 **Scale-up of PrEP, PEP, male circumcision**

LBPEC036 **The impact of pre-exposure prophylaxis with TDF/FTC on HIV diagnoses, 2012-2016, United States**
P.S. Sullivan, D.K. Smith, R. Mera-Giler, A. Siddiqi, B. Gunnels, N. Harris, X. Hu, L. Waller, S. McCallister
 United States

PEC037 **Integrating STI, sexual and reproductive health, HBV and HCV services in HIV prevention programs**

LBPEC037 **A cost-effective strategy to reach WHO hepatitis C virus elimination targets in men who have sex with men in the UK : 90% decrease in hepatitis C incidence by 2030**
L. MacGregor, Z. Ward, N. Martin, F. Hickson, P. Weatherburn, M. Hickman, P. Vickerman
 United Kingdom

PEC038 **Combination prevention strategies**
 LBPEC038 **Three-fold increases in population-level HIV viral-load suppression among men and young adults in a mixed urban-rural Tanzania lake-zone community: Intervention outcomes of the Bukoba Combination Prevention Evaluation (BCPE)**

C. Steiner, D. MckKellar, H. Cham, H. Maruyama, O. Rwabiyago, G. Kundi, O. Msumi, R. Weber, J. Byrd, E. Churi, S. Pals, C. Madevu-Matson, K. Kazaura, D. Mbilinyi, F. Morales, J. Justman, A. Rwebembera
 Tanzania, United Republic of

Track D > **Social and political research, law, policy and human rights**

PED039 **Social and behavioural concepts and theories**
 LBPED039 **Ninajiamini (I have confidence): Understanding the transformative effects of a participatory intervention in the Maisha Intimate Partner Violence (IPV) Trial in Tanzania**
S. Lees, G. Mshana, V. Selestine, M. Marchant, S. Harvey, S. Kapiga, C. Watts
 United Kingdom

PED040 **Growing up with HIV: specific needs and interventions for children and adolescents**
 LBPED040 **I have made friends with whom we remind and encourage each other: Youth perspectives on and access to a WhatsApp-based HIV treatment support tool in Nairobi, Kenya**
K. Ronen, C. Mugo, A. Muriithi, D. Seeh, C. Akinyi, H. Moraa, M. Nduati, B. Guthrie, M. Moreno, G. John-Stewart, I. Inwani
 Kenya

PED041-D042 **Ageing with HIV: evolving and additional needs and responses**
 LBPED041 **A comparison of clinical characteristics and behavioral risks between HIV-infected and non-infected older adults in Northern Thailand**
A. Tangmunkongvorakul, P. Musumari, K. Sriphanaviboonchai, W. Sitthi, K. Rerkasem
 Thailand

LBPED042 **Treatment team model for HIV, aging and long-term survivors**
C. Hutchinson, M. Adams, L. Angus, M. Beckles, D. Butler, J. Brooks, N. Collins, C. Fammons, D. Georgetti, J. Gorge, D. Ronning, S. Russo, B. Summer, M.A. Jones
 United States

PED044

	Other populations vulnerable in specific contexts
LBPED044	<p>Young female sex workers and men who have sex with men in Cameroon: Unmet need for HIV prevention and treatment services</p> <p><i>S. Ketende, A.L. Bowring, M. Njindam, G. Fako, A. Rao, C. Lyons, M. Decker, G. Turpin, G. Fouda, F. Ndonko, D. Levitt, U. Tamoufe, S. Billong, Z.-K. Bissek, O. Njoya, S. Baral</i> United States</p>
PED045	Adolescents, sexuality, and relationships
LBPED045	<p>Bringing CSE in the era of #digitalization: Comprehensive sexuality education advocacy through innovative online evidence-based approach</p> <p><i>P. Mladenov</i> Bulgaria</p>
PED046-D047	Policies addressing social and economic determinants of vulnerability
LBPED046	<p>HIV pre-exposure prophylaxis (PrEP) roll out at the National Program in Brazil</p> <p><i>T. Meireles D. Alencar, A.R. Pati Pascom, M. T. Santos Christ, I. Ornelas Pereira, C. H. Dutra Barros, M. Veloso Meireles, C. Pimenta, F. M. Rick, A. Schwartz Benzaken</i> Brazil</p>
LBPED047	<p>EQUIP Khethimpilo: Rapid scale up of viral load testing in an area previously challenged by access to viral lab support in Urban Setting in Zimbabwe: Lessons learnt</p> <p><i>E. Mothibi, A. Grimwood, C. Chikanda, J. Mangoma Chaurura, N. Nhando, N. Mabhena, B. Makumbe, F. Chirowa</i> South Africa</p>
Track E >	Implementation research, economics, systems and synergies with other health and development sectors
PED039	Social and behavioural concepts and theories
LBPED039	<p>Ninajiamini (I have confidence): Understanding the transformative effects of a participatory intervention in the Maisha Intimate Partner Violence (IPV) Trial in Tanzania</p> <p><i>S. Lees, G. Mshana, V. Selestine, M. Marchant, S. Harvey, S. Kapiga, C. Watts</i> United Kingdom</p>
PED040	Growing up with HIV: specific needs and interventions for children and adolescents
LBPED040	<p>I have made friends with whom we remind and encourage each other: Youth perspectives on and access to a WhatsApp-based HIV treatment support tool in Nairobi, Kenya</p> <p><i>K. Ronen, C. Mugo, A. Muriithi, D. Seeh, C. Akinyi, H. Moraa, M. Nduati, B. Guthrie, M. Moreno, G. John-Stewart, I. Inwani</i> Kenya</p>
PED041-D042	Ageing with HIV: evolving and additional needs and responses
LBPED041	<p>A comparison of clinical characteristics and behavioral risks between HIV-infected and non-infected older adults in Northern Thailand</p> <p><i>A. Tangmunkongvorakul, P. Musumari, K. Srithanaviboonchai, W. Sitthi, K. Rerkasem</i> Thailand</p>

LBPED042	Treatment team model for HIV, aging and long-term survivors
	<i>C. Hutchinson, M. Adams, L. Angus, M. Beckles, D. Butler, J. Brooks, N. Collins, C. Fammons, D. Georgetti, J. Gorge, D. Ronning, S. Russo, B. Summer, M.A. Jones</i> United States
PED044	Other populations vulnerable in specific contexts
LBPED044	<p>Young female sex workers and men who have sex with men in Cameroon: Unmet need for HIV prevention and treatment services</p> <p><i>S. Ketende, A.L. Bowring, M. Njindam, G. Fako, A. Rao, C. Lyons, M. Decker, G. Turpin, G. Fouda, F. Ndonko, D. Levitt, U. Tamoufe, S. Billong, Z.-K. Bissek, O. Njoya, S. Baral</i> United States</p>
PED045	Adolescents, sexuality, and relationships
LBPED045	<p>Bringing CSE in the era of #digitalization: Comprehensive sexuality education advocacy through innovative online evidence-based approach</p> <p><i>P. Mladenov</i> Bulgaria</p>
PED046-D047	Policies addressing social and economic determinants of vulnerability
LBPED046	<p>HIV pre-exposure prophylaxis (PrEP) roll out at the National Program in Brazil</p> <p><i>T. Meireles D. Alencar, A.R. Pati Pascom, M. T. Santos Christ, I. Ornelas Pereira, C. H. Dutra Barros, M. Veloso Meireles, C. Pimenta, F. M. Rick, A. Schwartz Benzaken</i> Brazil</p>
LBPED047	<p>EQUIP Khethimpilo: Rapid scale up of viral load testing in an area previously challenged by access to viral lab support in Urban Setting in Zimbabwe: Lessons learnt</p> <p><i>E. Mothibi, A. Grimwood, C. Chikanda, J. Mangoma Chaurura, N. Nhando, N. Mabhena, B. Makumbe, F. Chirowa</i> South Africa</p>

